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 Background : The indications for and the optimal mode of 
adjuvant therapy in surgically operated endometrial cancer 
patients have not yet been established. We studied the indica-
tions for the postoperative treatment of endometrial carci-
noma patients based on their surgical stages (FIGO, 1988) . 
 Methods : We retrospectively restaged the cases of 178 
endometrial carcinoma patients who underwent hysterec-
tomy with pelvic lymphadenectomy between 1965 and 1992 
and who were followed-up longer than 3 years. The patients 
were subdivided into low- and high-risk groups, and we 
investigated the relation between their postoperative treat-
ment and recurrence rates. Postoperative treatment was 
divided into the three groups of no/incomplete, external 
whole-pelvic irradiation (EWPI) and chemotherapy. 
 Results : The 79 patients in Stage Ia or Ib had no/incom-
plete postoperative treatment, but only 1 (1.3%) had a 
recurrence. Four Stage IIa patients had no recurrence and all 
3 low-risk patients had no postoperative treatment. Of the 5 
Stage IIb, low-risk patients, 1 of the no postoperative-
treatment group had a recurrence. The recurrence rate 
among the Stage IIb patients of the high-risk group was 40% 
(2/5) in the incomplete postoperative treatment group. The 
six Stage IIIa patients with EWPI. had no recurrence. In 
contrast, 14 of the 15 Stage IIIb and IIIc patients underwent 
postoperative EWPI, and 11 of them (78.6%) had a recurrence 
including 8 (81.8%) with a recurrence in distant regions. 
 Conclusion : Postoperative treatment may be well omitted 
for many patients at Stage Ia or Ib and the low-risk group at 
Stage IIa based on surgical staging criteria. Patients in other 
surgical stages seemed to require to identify best postopera-
tive treatment , but further randomized prospective studies 
will be required to identift the best mode of treatment.
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Introduction 
 In 1988, the International Federation of Gynecology and 
Obstetrics (FIGO )1) issued a system of surgical staging for 
endometrial carcinoma. According to this system, a 
determination the surgical stage is made based on the 
findings by laparotomy as well as on the routine clinical
examinations. Thus, laparotomy, hysterectomy and 
biopsies of all suspicious sites form the bases for staging. 
The final histologic findings after surgery (and cytologic 
findings when available) are also to be considered in the 
staging. However, the previously accepted FIGO guidelines 
for clinical staging (1983) are still relevant and should be 
used for the patients not primarily operated and those 
treated with radiation and/or chemotherapy. Accordingly, 
the surgical staging is not a substitute for the clinical 
staging. The clinical staging system has already been 
applied widely in Japan, and the surgical staging system 
was also accepted by the Committee on Gynecology and 
Oncology of the Japan Society of Obstetrics and 
Gynecology') in January 1996. 
 Since the surgical stage refers to the presence and degree 
of the major prognostic factors obtained histologically in 
endometrial carcinoma"), the surgical stage is considered 
to reflect prognosis better than the conventional clinical 
stage and can be used to individualize an appropriate 
postoperative therapy. In the present study, we retrospec-
tively analyzed a series of endometrial carcinoma patients 
to determine the relationship between postoperative 
treatments and recurrences by surgical stage.
Patients and Methods 
 As histological prognostic factors for endometrial 
carcinoma, the presence of vessel permeation,"") and 
specific histologic types"',"') (adenosquamous carcinoma, 
clear cell adenocarcinoma, serous adenocarcinoma, muci-
nous adenocarcinoma, squamous cell carcinoma, undiffer-
entiated carcinoma, and carcinosarcoma) have been 
established in addition to the factors involved in the 
surgical staging (histologic differentiation, depth of 
myometrial invasion, cervical involvement, vaginal or 
adnexal invasion, and lymph node metastasis). Thus, for 
the carcinomas at the same surgical stage, the presence of 
vessel permeation and specific histologic types may be 
important prognostic factors histologically. 
 We examined the cases of 178 patients who underwent
hysterectomy with pelvic lymphadenetomy for endo-
metrial carcinoma between 1965 and 1992 at the Nagasaki 
University School of Medicine. The patients were 25-76 
years of age, mean 53.0±10.6 years. We performed a 
surgical staging on the 178 cases retrospectively, and for 
each stage (Stage I in 126 cases, Stage II in 27 cases, and 
Stage III in 25 cases), the relation between postoperative 
treatments and recurrence was studied in two groups, the 
low-risk group and the high-risk group (Table 1), which 
were based on the histological prognostic factors not 
directly related to staging. This patients series included 
neither the cases in the low-risk group under Stage III nor 
those under Stage IV by surgical staging. 
 The histologic types and histologic differentiation were 
diagnosed according to the histologic classification of 
"The General Rules for Clinical and Pathological Manage -
ment of Uterine Corpus Cancer"'). For the sake of conven-
ience, the cases which corresponded to recurrence and 
relapse as definded in "The General Rules for Reporting on
Clinical Oncology"") were studied collectively as the 
recurrent cases in this study. 
 For the 151 patients treated in or after 1972, as a rule, 
the selection was made regarding the mode of operation 
and postoperative external irradiation ('Co whole-pelvic 
irradiation) based on clinical stages and histologic differ-
entiation (Table 2). For some of the patients among them, 
chemotherapy mainly consisting of Mitomycin C (MMC) 
[MMC alone or MMC+gestagen (4 patients), and 5-
fluorouracil+Cyclophosphamide+MMC in combination 
(FAM) or FAM+gestagen (5 patients)] was applied as a 
substitute for the external irradiation. For the 27 patients 
treated in or before 1971, simple hysterectomy and bilat-
eral adnexectomy, as well as the combination of these 
modes of operation with pelvic lymphadenectomy or 
radical hysterectomy, were performed, wherein 9 patients 
had external irradiation (8 patients) and MMC admini-
stration (1 patients), additionally. The patients who 
underwent extrapelvic radiation therapy in a total dosage
Table 1. Endometrial carcinoma patients treated between 1965 and 1992 at the Nagasaki University School of Medicine : 
low-and high-risk groups at each surgical stage.
Surgical stage Histological prognostic factor                                                                                         Groups (Cases)
   (Cases) Depth of myometrial Histologic 
               invasion differentiation Vessel permeation Histologic type 
 Stage I Stage la (none), Grade 1 _ Endometriod, Low -risk group* (70)  (126) lb (51/2) 
or Adenoacanthoma 
              Ic (>1/2) Grade 2,3 + Specific type High-risk group* *(56) 
 Stage II None, 51/2 Grade 1 _ Endometriod, Low-risk group* (8)  (27) Adenoacanthoma 
              >1/2 Grade 2,3 + Specific type High-risk group" (19) 
 Stage III None, 51/2 Grade 1 _ Endometriod, Low-risk group* (0)  (25) Adenoacanthoma 
              >1/2 Grade 2,3 + Specific type High-risk group" (25) 
   Consisting of cases that met all of the histologic prognostic factors. 
* * Consisting of cases in which one or more prognostic factor was associated.
Table 2. Selection of the surgical mode based on clinical stage and histologic differentation, and indication for postoperative 
irradiation.
    Clinical stage Histologic differentiation Surgical mode Indication for postoperative irradiation 
     Stage I Grade 1, 2 MRH*with pelvic Case with 1, 2, and/or 3                                                lymphadenectomy 1. Invasion to over 1/3 of myometrium 
                                                                          2. Carvical involvement 
                                                                       3. Lymph node metastasis 
                           Grade 3 RH* * All cases 
     Stage II, III Grade 1, 2, 3 RH** All cases 
* MRH : Modified radical hysterectomy 
* * RH : Radical hysterectomy
Table 3. Recurrence rate at each surgical stage among 178 endometrial carcinoma patients.
Surgical stage No. Recurrence 0                                   No . Rate(/o) 
    la 36 0 0 
    lb 64 1 1.6 3.2 
    IC 26 3 11.5 ~k    IIa 4 0 0 } 22.2 
    IIb 23 6 26.1 
    IIIa 10 2 20.0 ~k *k 
    IIIb 1 1 100 56.0 
    IIIc 14 11 78.6 
   Total 178 24 13.5 
                                                                  * p=0.0023, * *P=0.0217, * * *P<0.0001
Table 4. Recurrence in the Stage I (low-risk group) patients by postoperative treatment.
Surgical No/incomplete External irradiation Chemotherapy Total 
 stage N
o No. of No No. of No No. of No No. of                            recurrences recurrences recurrences recurrences
Stage Ia 24 0 1 0 0 25 0 
Stage Ib 27 0 7 0 3 0 37 0 
Stage lc 2 0 5 0 1 0 8 0 
 Total 53 0 13 0 4 0 70 0
of not more than 50 Gy (at point A) and those who 
underwent the MMC chemotherapy in a total dosage of 
not more than 40 mg were both included in the no/incom-
plete postoperative therapy group. 
 Thus, the postoperative therapy was studied after 
dividing the patients into 3 groups, namely, the extra-
pelvic radiation therapy group (70 patients), the chemo-
therapy group (10 patients), and the no/incomplete 
postoperative therapy group (98 patients).
Results 
 The prognosis for at least 3 years or longer was con-
firmed in all 178 of the patients enrolled as subjects in this 
study, wherein 24 patients (13.5%) revealed a recurrence 
histologically or clinically. Recurrence in the surgical 
stage was noted in 4/126 patients (3.2%) in Stage I, 6/27 
patients (22.2%) in Stage II, and 14/25 patients (56.0%) in 
Stage III, with a significant difference among these 3 
groups (Fisher's exact method) (Table 3). Further, when 
subdivided to each stage, an increasing trend of recurrence 
was noted according to the development of the lesion. 
Based on the surgical stages, the results studied in com-
parison with the postoperative therapy administered are 
explained below. 
1. Surgical Stage I 
1) Low-Risk Group in Stage I
 In the low-risk group in the Surgical Stage I (70 pa-
tients), no recurrence has been noted to date, and a fairly 
good number of patients, i.e., 24 of the 25 patients in Stage 
Ia and 27 of the 37 patients in Stage Ib have been treated by 
surgical operation alone (Table 4). 
 Among the patients in whom the depth of myometrial 
invasion was over % (Stage Ic), 5 of the 8 patients re-
quired external whole-pelvic irradiation and 1 patient 
needed MMC administration additionally, even though 
they belonged to the low-risk group, and no recurrence has 
been noted in them so far. Recurrence was also not noted in 
the 2 patients of the no/incomplete postoperative therapy 
group. 
2) High-Risk Group in Stage I 
 Eleven patients of the high-risk group at Stage Ia have 
not shown recurrence yet, including 10 patients treated 
with a surgical operation alone (Table 5). 
 In contrast, of the 18 patients at Stage Ib and 6 at Stage 
Ic, who underwent no or incomplete additional postopera-
tive treatment, one patient (5.6%) and 2 patients (33.3%) 
showed recurrence, respectively (Table 5). Of the 21 
patients with additional external whole-pelvic irradiation 
or MMC administration, recurrence has been observed in 
only 1 patient (4.8%). 
2. Surgical Stage II 
 Among the Stage IIa patients, 3 of the low-risk group 
patients had no postoperative treatment at all, and 1 
patient of the high-risk group had postoperative treatment
Table 5. Recurrence in the Stage I (high-risk group) patients by postoperative treatment.
                 No/incomplete External irradiation Chemotherapy Total 
  Surgical 
    stage N
o. Recurrence No. Recurrence No. Recurrence No. Recurrence                                                                                                     . 
                   No. Rate(%) No. Rate(%) No. Rate(%) No. Rate(%) 
 Stage Ia 10 0 0 1 0 0 0 11 0 0 
 Stage Ib 18 la 5.6 9 0 0 0 27 1 3.7 
 Stage Ic 6 2b 33.3 11 11 9.1 1 0 0 18 3 16.7 
 Total 34 3 8.8 21 1 4.8 1 0 0 56 4 7.1 
 ` Recurrence in distant region 
b Recurrence in pelvic cavity (1 patient) , and recurrence in distant region (1 patient)
Table 6. Recurrence in the Stage II (low-risk group) patients by postoperative treatment.
                          No External irradiation Total 
  Surgical 
    stage N
o Recurrence Recurrence Recurrence                       . No. No. 
                      No. Rate(%) No. Rate(%) No. Rate(%) 
 Stage IIa 3 0 0 0 3 0 0 
 Stage IIb 1 18 100 4 0 0 5 1 20.0 
 Total 4 1 25.0 4 0 0 8 1 12.5 
8 Recurrence in vagina
Table 7. Recurrence in the Stage II (high-risk group) patients by postoperative treatment.
                 No/incomplete External irradiation Chemotherapy Total 
  Surgical 
    stage N
o. Recurrence No. Recurrence No. Recurrence No. Recurrence 
. 
                  No. Rate(%) No. Rate(%) No. Rate(%) No. Rate(%) 
 Stage IIa 0 1 0 0 0 1 0 0 
 Stage IIb 5 2a 40.0 11 2b 18.2 2 1` 50.0 18 5 28.7 
 Total 5 2 40.0 12 2 16.7 2 1 50.0 19 5 26.3 
a Recurrence in distant region (1 patient) , and recurrence in pelvic cavity (1 patient) b Recurrence in pelvic cavity (1 patient) , and recurrence in distant region (1 patient) 
 Recurrence in vagina
by external whole-pelvic irradiation, and no recurrence has 
been observed in any of these four patients (Tables 6 and 
7). 
 Of the 5 cases in Stage IIb of the low-risk group, 1 
patient with no postoperative treatment had a vaginal 
recurrence, but the other 4 patients with external whole-
pelvic irradiation showed no recurrence (Table 6). Of the 
18 cases in Stage IIb of the high-risk group, 3 of the 13 
patients (23.1%) who underwent irradiation or chemo-
therapy had recurrence (Table 7). Two of these 3 patients 
with a recurrence had postoperative treatment by whole-
pelvic irradiation, but both of them developed the recur-
rence in the pelvic cavity of the irradiated field. 
3. Surgical Stage III 
 All of the 25 patients at surgical Stage III belonged to 
the high-risk group and included no patient in the low-risk 
group (Table 1). Of these 25patients, 23 completed postop-
erative treatment by external whole-pelvic irradiation or 
FAM therapy, and 13 of these 23 patients with postopera-
tive treatment (56.5%) had a recurrence. For 6 patients in 
Stage IIIa with external whole-pelvic irradiation, no 
recurrence has been observed so far (Table 8).
Table 8. Recurrence in the Stage III (high-risk group) patients by postoperative treatment.
                 No/incomplete External irradiation Chemotherapy Total 
  Surgical 
    stage N
o. Recurrence No. Recurrence No. Recurrence No. Recurrence                                                                                                 . 
                   No. Rate(%) No. Rate(%) No. Rate(%) No. Rate(%) 
 Stage IIIa 2 1 50.0 6 0 0 2 1 50.0 10 2 20.0 
 Stage II1b 0 1 1 100 0 1 1 100 
 Stage IIIc 0 13 10 76.9 1 1 100 14 11 78.6 
 Total 2 la 50.0 20 116 55.0 3 2` 66.7 25 14 56.0 
8 Recurrence in pelvic cavity 
b Recurrence in distant region (7 patients) , distant region and pelvic cavity (2 patients), pelvic cavity (1 patient), 
 and unknown (1 patient) 
 Recurrence in distant region and pelvic cavity (1 patient), and recurrence in pelvic cavity (1 patient)
 In the Stage IlIb and IlIc groups, postoperative treatment 
was applied to all 15 patients, and 14 of them had external 
whole-pelvic irradiation. However, 11 of these 14 patients 
(78.6%) had a recurrence, and 9 of them (81.8%) were in 
the distant region and, in some cases, included a pelvic 
cavity recurrence (Table 8).
Discussion 
 The optimal mode of treatment for endometrial carci-
noma has not yet been established by a unified consensus, 
which is different from the situation for cervical carci-
noma or ovarian carcinoma. For instance, in Europe and 
the U.S.A., preoperative irradiation for endmetrial carci-
noma has been applied frequently, which, however, has 
often reviewed negatively regarding its usefulness, because 
of the changes caused in the pathohistological images 
useful for the selection of treatment and as prognostic 
indicators, and because it does not much improve the 
therapeutic results compared with those by postoperative 
irradiation',"-"). The indications or mode of postoperative 
treatment for endometrial carcinoma have also not been 
established. To prevent such chaos in the management of 
endometrial carcinoma, it is necessary to use the FIGO 
surgical staging system, which incorporates important 
histopathological prognostic factors and accurately 
reflects prognosis, as confirmed by many researchers'-') and 
our present results; it is also important to prospectively 
compare, based on the FIGO system, the results produced 
by various modes of treatment. 
 Ackerman et al'). analyzed the relapse pattern in clinical 
Stage I endometrial carcinoma patients and indicated the 
inappropriateness of applying adjuvant pelvic irradiation 
as a routine technique to the patients with Grade 1 or 2 
endometrial carcinoma with less than 1/2 myometrial 
invasion or Grade 3 tumors confined to the endometrium.
In our present study, of the 79 patients at surgical Stage Ia 
(tumor limited to endometrium) and Ib (invasion to s1/2 
myometrium) treated surgically (simple or modified 
radical hysterectomy with pelvic lymphadenectomy) with 
no/incomplete postoperative treatment, only one patient 
(1.3%) had recurrence. This recurrent patient (surgical 
Stage Ib, Grade 2 endometrioid adenocarcinoma) was in 
Stage Ib of the high-risk group and was one of the 18 
patients (5.6%) with no/incomplete postoperative treat-
ment. These results indicate the possibility that the 
patients diagnosed as Stage Ia or lb by surgical staging can 
often be cured without postoperative treatment regardless 
of the grade of histologic differentiation, presence or 
absence of vessel permeation, or histologic type. 
 In the surgical Stage Ic (invasion > 1/2 myometrium ) 
gruop, 8 patients of the low-risk group had no recurrence 
regardless of the presence or absence of postoperative 
treatment. However, the sample number of this group was 
too small to make a definite conclusion, and we are thus 
now administering adjuvant whole-pelvic irradiation to all 
similar patients, as a rule. In Stage Ic of the high-risk 
group, 2 of the 6 patients with incomplete postoperative 
treatment had a recurrence, and 1 of the 12 patients with 
postoperative treatment had a recurrence. The number of 
samples for these results is too small to draw a conclusion, 
but it seemed necessary to apply postoperative treatment 
to surgical Stage Ic carcinomas in the high-risk group. 
However, some researchers indicate that postoperative 
adjuvant pelvic irradiation may be unnecessary in the 
patients with deep myometrial invasion by surgical 
staging, but without extrauterine invasion"',"). Thus, the 
significance of postoperative treatment in Surgical Stage 
Ic should be further examined. 
 Surgical Stage II is subdivided into IIa (endocervical 
glandular involvement only) and IIb (cervical stromal 
invasion) by cervical involvement. Therefore, the degree of 
myometrial invasion should be considered in classifying
risk groups in surgical Stages IIa and IIb (Table 1). 
Fanning et al"). treated 12 patients at surgical Stage IIa in 
the low-risk group by operation alone with no recurrence. 
We also treated 3 Stage IIa patients in the low-risk group 
by operation alone and there has been no recurrence so far. 
These results indicate that the impact of endocervical 
glandular involvement alone may be considerably small. 
Therefore, in surgical Stage IIa, the indication of postop-
erative treatment can be decided depending on the degree 
of myometrial invasion, i.e., in the same manner as in 
surgical Stages Ia, Ib and Ic. 
 In surgical Stage IIb, Fanning et al"). also reported a 
high incidence of recurrence (5 of 8 cases) (62.5%) treated 
by operation alone, which is in accord with our results. 
Postoperative treatment seemed to be necessary in the 
surgical Stage IIb patients for both the low-risk and 
high-risk groups, and the problem remains as to what kind 
of technique should be used. In our results, external 
whole-pelvic irradiation was useful in the 4 Stage IIb 
patients of the low-risk group. Considering that all of the 
5 recurrent patients in Stage IIb of the high-risk group 
reported by Fanning et a118). had extrauterine recurrence, it 
may be necessary to establish postoperative treatment for 
surgical Stage II patients. 
 In surgical Stage III, extrauterine invasion is found 
histopathologically and almost all the present such pa-
tients belonged to the high-risk group by our definition ; 
the choice of postoperative treatment will thus be an 
essential question. Schorge et al'). noted that postopera-
tive external whole-pelvic irradiation was not useful for 
surgical Stage llla (tumor invasion to serosa and/or 
adnexa and/or positive peritoneal cytology) or IIIb (vagi-
nal metastasis) patients. Our study results suggest the 
usefulness of this technique in 6 Stage IIIa patients. Since 
Stage IIIa mainly refers to intrapelvic invasion, the 
significance of postoperative whole-pelvic irradiation is 
worth further investigation. 
 In the surgical Stage IIIb and Stage IIIc (metastases to 
pelvic and/or paraaortic lymph nodes) patients of the 
present study, the postsurgical external whole-pelvic 
irradiation group frequently had an extrauterine recur-
rence ; extended-field irradiation or systemic chemother-
apy would thus be a reasonable selection for postoperative 
treatment. Of the patients classified as surgical Stage IlIc 
by pelvic lymph nodes metastasis, 67% of the patients also 
have paraaortic lymph node metastases'), and extended-
field irradiation including paraaortic lymph nodes and 
whole abdominal irradiation are recommended."-') How-
ever, few randomized prospective studies have been con-
ducted on postoperative systemic chemotherapy in 
endometrial carcinoma, and its usefulness has not been 
fully demonstrated. Recent phase II studies of advanced or 
recurrent cases found that the combinations of etoposide, 
cisplatin and 5-fluorouracil24), of paclitaxel and G-CSF, 
and of ifosfamide and mesna2&) were effective.
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